(NASDAQ: EQ) Equillium's forecast annual revenue growth rate of -1.66% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.04%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.92%.
Equillium's revenue in 2024 is $36,084,000.On average, 2 Wall Street analysts forecast EQ's revenue for 2024 to be $2,205,184,738, with the lowest EQ revenue forecast at $1,974,266,112, and the highest EQ revenue forecast at $2,436,103,363. On average, 1 Wall Street analysts forecast EQ's revenue for 2025 to be $1,939,011,360, with the lowest EQ revenue forecast at $1,939,011,360, and the highest EQ revenue forecast at $1,939,011,360.
In 2026, EQ is forecast to generate $1,106,999,213 in revenue, with the lowest revenue forecast at $1,106,999,213 and the highest revenue forecast at $1,106,999,213.